Abstract:Allosteric potentiators increase the affinity of endogenousagonist, in effect amplifying physiological control circuits. Because a potentiator should depend onendogenous tone, its effects are predicted to be self‐limiting and less proneto rapid tolerance development compared to direct‐acting agonists. Our objective was to test this hypothesis using DETQ, a novel allosteric potentiator of the dopamine D1 receptor. Although DETQ has high affinity for the human D1 receptor, it is 70‐fold less potent at the mouse and rat D1 receptors, limiting its use as a pharmacological tool in rodents. To overcome this limitation, we created a transgenic knock‐in mouse expressing the human D1 receptor (hD1). Homozygotes showed normal behavior and breeding. After oral dosing, DETQ caused a dose‐dependent 10‐fold increase in locomotor activity in habituated hD1 mice but not in wild‐type mice, implying a requirement for the human D1 receptor. The increase in locomotor activity was blocked by the D1 antagonist SCH39166 and by pretreatment with a high dose of reserpine, indicating that the behavioral response is dependent on endogenous dopamine release. At higher doses, the response to DETQ reached a plateau even though brain concentrations of unbound drug continued to rise. In contrast, the D1 agonists SKF82958 and A‐77636 showed bell‐shaped dose‐response curves, with a profound decrease in locomotor activity at the highest doses. The suppression of locomotor activity at high doses was due to engagement of competing stereotyped behaviors such as intense grooming. The stereotyped behaviors were not seen with DETQ, providing evidence that the response to DETQ is less liable to cause over stimulation. In repeated dosing over four days, the locomotor response to DETQ was maintained, whereas the response to A‐77636 showed rapid tolerance. In hD1 mice treated with a low dose of reserpine, DETQ restored locomotor activity to untreated control levels; this model is relevant to stand‐alone therapy in mild‐to‐moderate Parkinson's disease. Versus a higher dose of reserpine, DETQ acted synergistically with L‐DOPA in restoring locomotor activity. DETQ also increased wakefulness and decreased sleep and was found to be effective in a behavioral despair model. We also compared DETQ with SKF82958 for efficacy in the Y‐maze. While both compounds enhanced the number of arm entries in a dose–dependent fashion, mice treated with DETQ maintained spontaneous alternation even at high doses, whereas mice treated with higher doses of SKF82958 showed an increased prevalence to return to the same arm (asign of cognitive dysfunction). Finally, DETQ increased spontaneous eye blink rate in the rhesus monkey, a response related to central D1 activation. These results confirm that D1 potentiators may possess advantages over D1 agonists for the treatment of Parkinson's disease and other CNS disorders.

The D2-like Dopamine Receptor Agonist Quinpirole Microinjected Into the Ventral Pallidum Dose-Dependently Inhibits the VTA and Induces Place Aversion

The dose-dependent effect of the D2R agonist quinpirole microinjected into the ventral pallidum on information flow in the limbic system

Effects of Quinpirole in the Ventral Tegmental Area on Impulsive Behaviour During Performance on the Five-Choice Serial Reaction Time Task

Dopamine D2/D3 Receptor Agonist Quinpirole Impairs Spatial Reversal Learning in Rats: Investigation of D3 Receptor Involvement in Persistent Behavior

Longlasting consequences of chronic treatment with the dopamine agonist quinpirole for the undrugged behavior of rats

Effects of intrastriatal injection of the dopamine receptor agonist SKF38393 and quinpirole on locomotor behavior in hemiparkinsonism rats

The modulatory role of accumbens and hippocampus D2 receptors in anxiety and memory

Down-Regulation of Stereotyped Behavior and Production of Latent Locomotor Behaviors in Mice Treated Continuously with Quinpirole

Influence of an Adenosine Receptor Antagonist on Neurotransmitters in Parkinsonian Mice.

Application of Quinpirole in the Paraventricular Thalamus Facilitates Emergence from Isoflurane Anesthesia in Mice.

D2 Receptors and Cognitive Flexibility in Marmosets: Tri-Phasic Dose–response Effects of Intra-Striatal Quinpirole on Serial Reversal Performance

D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse

Modulating sensory gating in healthy volunteers: The effects of desipramine and haloperidol

VTA glutamatergic projections to the nucleus accumbens suppress psychostimulant-seeking behavior

Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate

The antipsychotic agent sulpiride microinjected into the ventral pallidum restores positive symptom-like habituation disturbance in MAM-E17 schizophrenia model rats

Opposing roles of prelimbic and infralimbic dopamine in conditioned cue and place preference

Behavioral Effects of a Novel Allosteric Potentiator of the Dopamine D1 Receptor in Human D1 Knock-in Mice and Rhesus Monkeys

Study of ππ phase shifts in ψ(2S)→π+π-J/ψ

In Vivo Administration of an Oligodeoxynucleotide Antisense to the D2 Dopamine Receptor Messenger RNA Inhibits D2 Dopamine Receptor-Mediated Behavior and the Expression of D2 Dopamine Receptors in Mouse Striatum.

The Allosteric Dopamine D1 Receptor Potentiator, DETQ, Ameliorates Subchronic Phencyclidine-Induced Object Recognition Memory Deficits and Enhances Cortical Acetylcholine Efflux in Male Humanized D1 Receptor Knock-in Mice.